Piramal Profits As It Sheds DRG To Clarivate For $950m
An experienced hand at M&A, Ajay Piramal has done it again – this time selling Decision Resources Group to Clarivate...
Scrip - January 20, 2020

QUOTED. 20 January 2020. Henrik Berggren.
San Francisco-based digital health start-up Steady Health has launched the first "virtual" full-service diabetes clinic for patients in California. See...
Scrip - January 20, 2020

New EU Patent System On Track For End Of 2020, Says EPO
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all...
Pink Sheet - January 17, 2020

In Vivo's Top M&A Of 2019: Cast Your Vote!
It is time for In Vivo's 12th annual Deals of the Year contest. We've selected 15 nominees in three categories...
In Vivo - January 16, 2020

What Does 2020 Hold For Biopharma?
Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what...
In Vivo - January 16, 2020

A Tale Of Two Pipelines
Immuno-oncology has produced some exciting successes, but the field has become intensely crowded. Enormous resources are being poured into duplicative...
In Vivo - January 16, 2020

Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 4)
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator...
Medtech Insight - January 17, 2020

QUOTED. 17 January 2020. Kyle Sheetz.
The rapid adoption of robotic-assisted surgery must be carefully monitored to ensure surgeons' enthusiasm for this technology does not compromise...
Medtech Insight - January 17, 2020

Health And Wellness Trademark Review 14 January, 2020
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the...
HBW Insight - January 18, 2020

Aptinyx nets $33.6mm through FOPO
Neurology-focused Aptinyx Inc. (N-methyl-D-aspartic acid (NMDA) receptor discovery platform) netted $33.6mm through the public sale of 11.7mm shares (including the overallotment) at $3. The company will use the proceeds to advance its NMDA receptor modulator pipeline, including NYX2925 (Phase II for diabetic peripheral neuropathy and fibromyalgia indications and preclinical for chemotherapy-induced peripheral neuropathy); NYX783 (Phase II for post-traumatic stress disorder and preclinical for alcohol use disorder); and NYX458 (Phase II for Parkinson’s diseases and preclinical for traumatic brain injury).
Strategic Transactions - January 18, 2020

Novartis grants Iovance license to its IL-2 analog to develop as cancer immunotherapy
Iovance Biotherapeutics Inc. gained development and commercialization rights to an antibody cytokine engrafted protein from Novartis AG.
Strategic Transactions - January 18, 2020

Takeda gains exclusive worldwide option for up to four Shattuck ARC immuno-oncology programs
Takeda Pharmaceutical Co. Ltd.’s Takeda Oncology division (formerly Millennium Pharmaceuticals) entered into an exclusive option agreement for a global license that employs Shattuck Labs Inc.’s Agonist Redirected Checkpoint (ARC) fusion protein platform, which enables the creation of combination cancer immunotherapy using a single product.
Strategic Transactions - January 18, 2020